Abiopharma

🔍 Ryan Christopher Michael (Executive)

Company: Gevo, Inc. (GEVO)

Report Date: 2025-09-04

Detailed Transactions and Holdings:

• Sold 1,683 shares of Common Stock at $1.6295 per share (Direct)
  Date: 2025-09-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,631,938.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-04 | Code: H | nature_of_ownership: By 401(k) Plan | shares_owned_after: 22,016.68 | Footnotes: F3

Footnotes:

• F1: Represents shares sold by the Reporting Person to cover tax withholding obligations upon vesting of a restricted stock award. The reported sales were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.61 to $1.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: Between August 5, 2025 and September 4, 2025, the reporting person disposed of 8.35 shares of the issuer's common stock under the issuer's 401(k) plan to cover administrative fees. The information in this report is based on a plan statement dated August 25, 2025.